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Background: Pneumonia is a leading cause of morbidity and mortality in children.
Objective: The aim of study was to evaluate the efficacy of Zinc supplementation in treatment of severe
pneumonia in hospitalized children.
Design/Methods: A double blind randomized, placebo- controlled clinical trial conducted at a tertiary care centre
of a teaching hospital. Children with diagnosis of severe pneumonia were randomly assigned to receive
supplementation with either elemental zinc or placebo by mouth at the time of enrollment. From day 2, they
received 10 mg of their assigned treatment by mouth twice a day for 7 days along with standard antimicrobial
therapy.
Results: The baseline characteristics like age, sex, weight, weight Z score, height, height Z score, weight for height
Z score and hemoglobin were comparable in both study groups. The respiratory rate, chest indrawing, cyanosis,
stridor, nasal flaring, wheeze and fever in both groups recorded at enrollment and parameters did not differ
significantly between the two groups. The outcome measures like time taken for resolution of severe pneumonia,
pneumonia, duration of hospital stay, nil per oral, intravenous fluid, oxygen use, treatment requiring 2nd line of drug
and 3rd line drug were evaluated and found to be same.
Conclusion: The present study did not show a statistically significant reduction in duration of severe pneumonia, or
reduction in hospital stay for children given daily zinc supplementation along with standard antimicrobial therapy.
Therefore, zinc supplementation given during the acute episode does not help in short term clinical recovery from
severe pneumonia.
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Worldwide, pneumonia is the leading cause of pediatric
morbidity and mortality. It is estimated that pneumonia
is responsible for >2 million deaths each year in children
below 5 years of age, and contributes 20% of the annual
deaths in this age group [1]. Approximately 95% of the
pneumonia-related deaths occur in developing countries,
and the younger age groups have the highest risk of
death. Zinc supplementation lowers the risk of acute re-
spiratory illnesses and diarrhea in children [2]. A recent
clinical trial conducted in Bangladesh suggested that
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reproduction in any medium, provided the ortherapy can significantly shorten the duration of severe
pneumonia, tachypnea, hypoxia, and chest indrawing and
duration of hospital stay for young children with pneu-
monia [3]. However, therapeutic trials of Zn conducted
in Indian hospitalized children with severe pneumonia
demonstrated no overall effect [4,5]. Valentiner-Branth
et al. [6] demonstrated that Zn neither reduced the
risk of treatment failure nor hasten the recovery of
non-severe or severe pneumonia in Nepalese children
between 2–35 month of age. Many children in Nepal,
especially below 5 years of age, are admitted with severe
pneumonia in pediatric wards requiring antimicrobial
therapy with prolonged hospital stay. In view of previous
studies, which have evaluated the role of zinc in children
with pneumonia either below 2 or 3 years of age with
variable reports [3,6]. The present study was undertakend. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Study flow.
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treatment of severe pneumonia, beside standard anti-
microbial therapy, in hospitalized Nepalese children, aged
2 months to 5 years, by comparing the different outcome
measures between zinc supplemented and placebo
groups.
Patients and methods
Study design and setting
This study was a randomized, double-blind, placebo-
controlled clinical trial conducted between June 2008 to
August 2009 at Department of Pediatrics, B. P. Koirala
Institute of Health Sciences, Dharan, Nepal. This trial
was registered in the CTRI Website and CTRI No. is:
CTRI/2008/091/00006.
Children between 2 months to 5 year of age admitted
to the pediatric wards were assessed and considered
eligible for enrollment in the trial if they fulfilled the
criteria for a diagnosis of severe pneumonia. Severe
pneumonia was defined as per WHO/IMCI (Integrated
Management of Childhood illness) guide line [7] and
whose parents provided written informed consent were
included in the study. Patients who had congenital
cardiac or renal disease, severe malnutrition (as defined
by WHO), concomitant diarrhea, severe anemia
(Hemoglobin <8 g/dl), complicated pneumonia, congeni-
tal lung anomalies, chronic cough, documented tubercu-
losis, recurrent wheezing and children who were
receiving zinc supplements were excluded from the
study. Written consent was obtained after the parents or
guardians read study information. If the parents or
guardians were illiterate, the content of the written con-
sent was read to them, and consent was documented
by a thumbprint impression of one of the parents or
guardians in the presence of an unrelated witness. The
study was approved by the Institute Ethical Committee
and project review board of B. P. Koirala Institute of
Health Sciences. A detailed history, physical and sys-
temic examinations were carried out and recorded in a
predesigned data sheet at the time of enrollment. The
randomization codes were generated by the Deurali
Janta Pharmaceutical, Nepal who provided the coded
medicine strips for study. The codes were broken only
at the end of study.
Intervention
We calculated the sample size using EPI Info (WHO
recommended software for sample size) with an effect
size of 20%, 5% chance of type I and 10% chance of type
II error, keeping Odds ratio 3 times more benefit in sup-
plemented group. This calculation resulted in a sample
size of 55 in each group. Children with a diagnosis of se-
vere pneumonia were randomly assigned to receive sup-
plementation with either elemental zinc or placebotablets. Each tablet contained 10 mg zinc sulfate or
10 mg placebo. The zinc and placebo tablets were identi-
cal in appearance, consistency and taste. The supple-
ments were formulated and manufactured as dispersible
tablets by Deurali Janata Pharmaceuticals, Nepal and
packaged in a strip of 10 tablets. The back of strip was
labeled with identification number. Children received
20 mg of either zinc sulfate or placebo by mouth at the
time of enrollment. From day 2, they received 10 mg of
their assigned treatment by mouth twice a day for total
of 7 days. All enrolled children were treated according
to the standard protocol for treatment of severe pneu-
monia. The primary outcome measures were decrease in
duration of severe pneumonia and pneumonia and sec-
ondary outcome measures were decrease in duration of
nil per orally, intravenous fluid, use of oxygen and treat-
ment failures requiring 2nd and 3rd line antibiotics treat-
ment as defined in treatment protocol. They were
treated parentally with a combination of cefotaxime and
gentamicin if the age of child was less then 1 year and
with cefotaxime alone when the age of child was more
than 1 year. Patients who failed to improve within 48 hr
on this regimen, cloxacillin was added. If not improved
within next 48 hr with cloxacillin, then it was replaced
by vancomycin. If any suspicion about Chlamydia or
Mycoplasma was there, then azithromycin was added.
Follow up during hospital stay
During hospitalization, the child’s condition was assessed
8 hourly. Respiratory rate was measured for a full one
min. The count was done at a time when the child was
not crying. Pulse oximetry was measured with the use of
a probe (Nellcor Inc, Hayward, CA) placed on a finger
or toe. Axillary temperature was measured by using a
standard mercury thermometer. The presence of cough,
crepitations, wheezing, chest indrawing, cyanosis, inabil-
ity to feed, and lethargy/unconsciousness were also
Table 1 Baseline characteristics in zinc and placebo group
Characteristics Zinc group n=64 Placebo group n=53 P- value
Age (years) 9 (5.0,14.7) 10 (6.0,18.5) 0.116*
Gender n (%) Male Female 43 (67% 21 (32.8%) 33 (62.3%) 20 (37.7%) 0.578**
Weight (Kg) 7.92 +2.08 8.27 +2.13 0.382***
Weight Z score −1.05(−1.577, 0.040) −1.25 (−2.28, −0.180) 0.074*
Height (cm) 70.98 +8.45 73.37 +11.42 0.196***
Height Z score −875(−2.12, 0.385) −1.38(−2.72, 0.70) 0.249*
Weight-for-height Z score −0.510(−1.41, 0.830) −0.770(−1.77, 0.275) 0.241*
Hemoglobin (g/dl) 10.6 +1.3 10.4 +1.1 0.431***
Data are expressed as median, mean + SD, Figures in parentheses indicate interquartile range.
*Mann Whitney U test, ** Z test, *** Student’s t test.
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spiratory distress improved and oxygen saturation was
≥93%, and the baby was able to tolerate small sips of
feeds. Feeds were started as early as possible to optimally
balance fluid and caloric intake. Oral antibiotic cefpo-
doxime proxetil was started when the child was feeding
well and when oxygen saturation and respiratory rate
were stabilized. Once the patient was on oral antibiotic,
he or she remained under observation in the ward for a
further 24 hr before discharge. Study subjects were dis-
charged when they were being fed entirely with oral
feeds, the respiratory rate was normalized, oxygen satur-
ation was ≥93%, and the attending pediatrician decided
that the patient’s clinical condition had resolved and did
not require further hospital stay.
Statistical analysis
The data was analyzed by using SPSS Version 12.0
software. The Student’s t test was used of data showing
normal distribution and Mann Whitney U test for
non-Gaussian distribution. Chi-square and Z tests were
used for comparisons of proportions as appropriate, to
assess the treatment group differences. A p value
<0.05 was considered as statistically significant.
Results
Between June 2008 and August 2009, 122 children who
were eligible for participation in the trial (Figure 1); fiveTable 2 Clinical signs and symptoms in zinc and placebo grou
Characteristics Zinc n = 64
Respiratory rate at enrolment Mean (SD) 64 (8)
Chest indrawing n (%) 64 (100%)
Stridor n (%) 6 (9.3%)
Cyanosis n (%) 17 (26.6%)
Nasal flaring n (%) 22 (34.4%)
Wheeze n (%) 43 (67.2%)
Fever n (%) 64 (100%)
n – Number of cases, *Student’s t test, **Z test.children were excluded from the study as because they
did not meet the inclusion criteria due to detection of
congenital heart disease. The remaining 117 children
were enrolled, and 64 were randomly assigned to take
Zinc tablet and 53 were assigned to take placebo which
was not known to us as it was randomized, double blind
controlled trial. Baseline characteristics of the children
between placebo and zinc treatment groups like age, sex,
weight, weight Z score, height, height Z score, weight
for height Z score and hemoglobin were comparable
(Table 1). The clinical sign and symptoms like respira-
tory rate, chest indrawing, stridor, cyanosis, nasal flaring,
wheeze and fever were evaluated and no significant dif-
ferences were found between zinc and placebo groups
and observations are shown in Table 2.
The outcome measures between the two groups like
median duration of severe pneumonia, pneumonia,
hospitalization, nil per orally, intravenous fluid, oxygen
use, treatment requiring 2nd line and 3rd line drugs were
compared. It was observed that none of the parameters
were statistically significant between zinc and placebo
groups (Table 3).
Discussion
Zinc plays an important role in the development and
maintenance of host defense against infections [8,9]. The
therapeutic benefit of oral zinc in diarrhea has been well
documented in a Cochrane review of 18 trials whichps








Table 3 Comparison of Outcomes in Zinc and Placebo Groups
Outcome Zinc n= 64 Placebo n =53 P
Duration of hospitalization (hours) 73.5 (49.5,107.5) 72 (48.0,87.7) 0.193*
Duration of severe pneumonia (hours) 34.2 (21.0,48.0) 26 (16.0,46.0) 0.219*
Duration of pneumonia (hours) 40 (24,54.2) 43 (18.5,72.0) 0.943*
Duration of nil-per-orally (hours) 10 (0.0,23) 12 (0.0,18) 0.771*
Duration of intravenous fluid (hours) 22.0 (12.0,31.0) 16 (1.5,32.5) 0.258*
Duration of oxygen use (hours) 10 (0.0,22.0) 11.0 (0.0,23.5) 0.684*
Treatment failure requiring 2nd line drugs 14 (21.9%) 15 (28.3%) 0.423**
Treatment failure requiring 3rd line drugs 1 (1.6%) 1 (1.9%) 0.893**
n - Numer of cases, Data are expressed as median, Figures in parentheses indicate interquartile range and percentage.
*Mann Whitney U test, ** Z test.
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with acute or persistent diarrhea in the age group of
6 months to 5 years [10] Further, it has also been shown
that routine zinc supplementation lowers the risk of
acute respiratory infections and clinical pneumonia in
children [2].
Keeping these considerations, the present study was
carried out to find out the influence of co-administration
of zinc with standard antimicrobial therapy in a double-
blind randomized controlled clinical trial with primary
outcome measures as reduction in duration of severe
pneumonia and pneumonia. Overall basic characteristics
and clinical signs and symptoms were comparable be-
tween zinc and placebo groups. We did not find any sta-
tistically significant median reduction in duration of
severe pneumonia, pneumonia, hospital stay, nil per or-
ally, intravenous fluid, duration of oxygen use, treatment
requiring 2nd line or 3rd line antibiotic drugs in zinc sup-
plemented in comparison to placebo group along with
standard antimicrobial therapy. Other studies [4,5] also
did not find any positive benefit of reduction in duration
of severe pneumonia or pneumonia in zinc supplemented
group. Recently, a study from our country also demon-
strated that adjuvant zinc neither reduced the risk of
treatment failure nor hasten the recovery from non- se-
vere or severe pneumonia in Nepalese children in the age
group of 2–35 months of age [6]. In contrast, results
from a trial in Bangladesh suggested that zinc supple-
mentation given with empiric antimicrobial therapy sig-
nificantly shortened the duration of severe pneumonia,
tachypnoe, hypoxia, and chest indrawing and the hospital
stay for young children with pneumonia. The difference
in outcome in different trials could be better explained if
pre and post- treatment plasma zinc levels estimation
would have been done. As such benefit is expected if
children are in zinc deficient state. In our study, con-
comitant severe malnutrition cases were excluded,
which often have co-existing zinc deficiency. Therefore,
it may be possible that study population was not zinc
deficient and benefit of zinc therapy was not found.However, it is a matter of conjecture and difficult to
conclude as plasma level of zinc was not estimated.
We could identify no sub-group that benefited from
zinc supplementation especially when the data was
analyzed in relation to those cases t had wheezing also.
Similar was the observation reported by Brooks et al.
also in their study [3].Conclusion
This study did not show a statistically significant reduc-
tion in duration of severe pneumonia, and duration of
pneumonia as primary outcome measures. The duration
of hospitalization, nil per orally, oxygen use and treat-
ment failure were comparable between zinc and placebo
group. Thus, it appears that zinc supplementation given
during acute episode does not help in short- term clin-
ical recovery from severe pneumonia in non- malnour-
ished children.What is already known on this topic
Zinc supplementation in treatment of severe pneumonia
in children, aged 2 to 35 months, demonstrated incon-
sistent results.What this study adds
Zinc therapy does not shorten the duration of severe
pneumonia or pneumonia in hospitalized children be-
tween 2 months to 5 years of age.
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